<DOC>
	<DOC>NCT00508287</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117</brief_summary>
	<brief_title>Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Diagnosis of Type 2 diabetes for ≥ 3 months treated with metformin, thiazolidinedione, or sulfonylurea (either monotherapy or combination) or diet alone (drug naïve) Fasting plasma glucose: 126 240 mg/dL Hemoglobin A1c: 6 10% Estimated CrCl ≥ 60 mL/min ALT ≤ 1.5 x ULN and total bilirubin ≤ 2 x ULN Stable and well controlled hypertension and/or dyslipidemia Concomitant medications used for hypertension and/or dyslipidemia, thyroid hormone replacement therapy and low dose aspirin will be allowed if stable for at least 6 weeks Women of childbearing potential Symptomatic diabetes with polyuria and/or polydipsia History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome History of renal disease including diabetic nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>